Japan’s Takeda expects $200 million operating loss related to Novartis’ Xiidra withdrawal

Takeda Pharmaceutical Co Ltd 4502.T> said on Monday it anticipates an operating loss of about $200 million related to Novartis AG’s decision to withdraw a marketing application for the dry-eye drug …
( read original story …)

---